CVR number 19301540
Industry 46.4610 Wholesale of pharmaceutical goods

MEDILINK A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  0.6% 0.8% 0.8% 1.0% 1.2%  
Credit score (0-100)  98 92 90 86 80  
Credit rating  AA AA A A A  
Credit limit (kDKK)  1,412.8 1,623.9 1,219.5 744.1 340.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  18,871 8,194 9,983 11,357 11,228  
EBITDA  2,787 6,495 7,970 8,926 8,943  
EBIT  2,787 6,379 7,866 8,824 8,896  
Pre-tax profit (PTP)  2,462.5 6,336.5 7,838.6 9,022.2 8,767.9  
Net earnings  1,913.2 4,980.3 6,133.9 7,041.8 6,883.7  
Pre-tax profit without non-rec. items  2,462 6,337 7,839 9,022 8,768  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  244 179 126 73.4 39.5  
Shareholders equity total  9,323 13,803 9,937 8,979 8,863  
Interest-bearing liabilities  3,308 2,338 8,062 11,778 3,935  
Balance sheet total (assets)  18,131 21,720 23,504 28,420 18,435  
Net Debt  2,970 1,168 7,909 11,778 3,935  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  18,871 8,194 9,983 11,357 11,228  
Gross profit growth  16.7% -56.6% 21.8% 13.8% -1.1%  
Employees  10 1 1 3 3  
Employee growth %  0.0% -90.0% 0.0% 200.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  18,131 21,720 23,504 28,420 18,435  
Balance sheet change%  -9.5% 19.8% 8.2% 20.9% -35.1%  
Added value  2,787.2 6,495.1 7,969.8 8,927.6 8,942.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  17 -231 -208 -206 -93  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  14.8% 77.9% 78.8% 77.7% 79.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  15.3% 33.0% 35.2% 35.4% 38.7%  
ROI %  20.9% 45.6% 46.6% 47.4% 54.0%  
ROE %  22.9% 43.1% 51.7% 74.5% 77.2%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  51.4% 63.5% 42.3% 31.6% 48.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  106.6% 18.0% 99.2% 131.9% 44.0%  
Gearing %  35.5% 16.9% 81.1% 131.2% 44.4%  
Net interest  0 0 0 0 0  
Financing costs %  8.3% 8.5% 2.3% 1.7% 3.7%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.8 1.6 1.2 0.9 0.9  
Current Ratio  2.0 2.7 1.7 1.5 1.9  
Cash and cash equivalent  337.9 1,170.4 152.9 0.0 0.0  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  8,789.8 13,494.2 9,717.3 8,847.4 8,823.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  279 6,495 7,970 2,976 2,981  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  279 6,495 7,970 2,975 2,981  
EBIT / employee  279 6,379 7,866 2,941 2,965  
Net earnings / employee  191 4,980 6,134 2,347 2,295